Home > Boards > US Listed > Biotechs > NantKwest (NK)

I have to admit that I'm surprised to

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
knoxlube Member Profile
 
Followed By 5
Posts 1,293
Boards Moderated 0
Alias Born 05/08/11
160x600 placeholder
NantKwest Launches First-in-class, First-in-human Phase I Clinical Trial With a Targeted PD-L1 t-haNK Cell Therapy in Patient... Business Wire - 6/24/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/10/2019 4:04:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/7/2019 4:48:53 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/7/2019 4:45:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/7/2019 4:42:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/7/2019 4:40:28 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/7/2019 4:36:37 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 6/7/2019 4:32:37 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/7/2019 4:07:44 PM
Cheryl Cohen Appointed to NantKwest’s Board of Directors Business Wire - 6/6/2019 4:10:00 PM
NantKwest Announces Durable Complete Responses in Multiple Advanced-Stage Solid Tumor Cancers Following Off-the-Shelf NK Cell... Business Wire - 6/4/2019 8:00:00 AM
NantKwest Announces Updated Clinical Results for Nanatinostat (VRx-3996), a Novel HDAC Inhibitor Being Developed in Partnersh... Business Wire - 6/4/2019 7:45:00 AM
NantKwest Launches First-in-Human Targeted NK Phase I Clinical Trial of CD19 T-haNK Cell Therapy in Lymphoma Patients Business Wire - 6/3/2019 2:50:00 PM
NantKwest to Present and Provide Update at Upcoming Jefferies 2019 Annual Healthcare Conference Business Wire - 6/3/2019 8:00:00 AM
NantKwest, NantCell & NantOmics to Provide Updated Preclinical & Clinical Data in Four Abstracts at Part of the American Soci... Business Wire - 5/31/2019 8:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/8/2019 4:10:11 PM
Brink Biologics Announces Research License Agreement with Worcester Polytechnic Institute for Use of NantKwest’s NK-92®... Business Wire - 5/1/2019 8:00:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/26/2019 4:13:38 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 4/1/2019 4:09:04 PM
NantKwest Announces New haNK Natural Killer Cell Patent Issuance Further Expanding Intellectual Property Estate Business Wire - 4/1/2019 8:00:00 AM
NantKwest Chairman & CEO Dr. Patrick Soon-Shiong Exercises $39 Million in Warrants & Options in Support of NK’s Natural Kil... Business Wire - 3/25/2019 8:00:00 AM
NantKwest Chairman & CEO Dr. Patrick Soon-Shiong to Present Vision for Next Generation Natural Killer Cell Therapies During K... Business Wire - 3/18/2019 5:00:00 AM
Annual Report (10-k) Edgar (US Regulatory) - 3/13/2019 4:09:58 PM
NantKwest Signs Worldwide License Agreement with ProMab Biotechnologies to Exclusively Develop Select Next Generation Target... Business Wire - 3/4/2019 8:00:00 AM
NantKwest Announces Launch of Merkel Cell Carcinoma Phase II Trial Deploying Novel Triple Combination of off-the-Shelf Natura... Business Wire - 1/9/2019 8:00:00 AM
knoxlube   Monday, 03/25/19 02:20:10 PM
Re: None
Post # of 1171 
I have to admit that I'm surprised to see such a spike in volume and PPS just because SOON exercised his Warrants at $2. Maybe that signaled that NK shares are worth at least that much now and probably more later. I'm not really sure what to make of it all except I sold all my shares between $1.7-1.80, but may regret that later. Will see. Just wish some of this good happening with NK carried over to my MUCH bigger investment and Soon's partner in one of his key licensed drugs, Aldox, and it's developer, CYTR!

All IMO. GLTA in NK and CYTR!

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist